l General Information |
Product Name | KX2-391 |
General description | KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src. |
Synonym | N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide; KX 01 |
Purity | ≥98.0%(HPLC) | CAS Number | 897016-82-9 |
Formula | C26H29N3O3 | Molecular Weight | 431.53 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. |
Application | KX2-391 is an orally active Src kinase inhibitor with excellent bioavailability. In pre-clinical animal models, KX2-391 inhibits the growth of both primary tumors and metastasis. The compound is a potent inhibitor of a wide range of human tumor cells, including cells that are resistant to currently available cancer therapies. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
